Objectives To assess the effectiveness of the HPV vaccines in preventing genital warts in
young women. Design Population-based study using health databases. Setting Valencian …

Objectives To assess the effectiveness of the HPV vaccines in preventing genital warts (GW)
in women aged 14–23 years and to estimate the incidence of GW in the whole population …

Background Approximately 90% of genital warts (GWs) are caused by human
papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine …

Genital warts (GWs) are common, with about 5% to 10% of people having at least one
episode in their lifetime. They develop about 2–3 months after infection with human …

Background The quadrivalent human papillomavirus (HPV) vaccine has been assumed to
give protection against genital warts (GW) as well as cervical cancer. Our main question was …

Background. A reduction in the incidence of genital warts (GWs) is one of the first markers of
the effectiveness of vaccination against human papillomavirus (HPV) at the population level …

Objective Genital warts are the most common sexually transmitted disease and have a
detrimental impact on quality of life. Genital warts could be prevented by prophylactic HPV …

Background. Reducing the number of doses in the human papillomavirus (HPV) vaccination
regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …

Background: Genital warts (GW) are common and increasing in young people. Ninety
percent of GW are due to Human Papillomavirus (HPV) types 6 and 11. The objective of this …